Expected IOP Reduction with Timolol, Vyzulta, Zolymbus, and Acetazolamide
You can expect approximately 25-30% IOP reduction with timolol, 28-33% with Vyzulta (latanoprostene bunod), 10-20% with Zolymbus (netarsudil), and 20-30% with oral acetazolamide, based on the most recent guideline data and FDA-approved labeling.
Individual Medication Effects
Timolol (Beta-Blocker)
- IOP reduction: 26-27% at trough, 27% at peak 1
- Absolute reduction of approximately 7 mmHg from baseline 2
- The Glaucoma Laser Trial demonstrated timolol lowered IOP by 7 mmHg over 2 years 2
- Meta-analysis data shows relative reductions of -27% at peak and -26% at trough 3
Vyzulta/Latanoprostene Bunod 0.024%
- IOP reduction: 28-33% depending on time of day
- Provides superior IOP lowering compared to timolol throughout the 24-hour period 4, 5
- In the APOLLO study, Vyzulta demonstrated significantly lower mean IOP than timolol 0.5% at all 9 measurement time points over 3 months 5
- Particularly effective at nocturnal IOP control, reducing IOP 2.3 mmHg more than timolol during sleep 4
- Works through dual mechanism: prostaglandin analog effect (uveoscleral outflow) plus nitric oxide donation (trabecular meshwork relaxation) 6, 7
Zolymbus/Netarsudil (Rho Kinase Inhibitor)
- IOP reduction: 10-20% 1
- This is the least potent of the four medications listed
- Shown to be noninferior to timolol only in patients with baseline IOP <25 mmHg 8
- Unique advantage: reduces IOP to similar degree regardless of baseline pressure 8
- Most common side effect is conjunctival hyperemia 1, 8
Acetazolamide (Oral Carbonic Anhydrase Inhibitor)
- IOP reduction: 20-30% 1
- When given as 500 mg orally every 12 hours, produces mean reduction of 48.6% from baseline 9
- Provides substantial additive effect when combined with timolol
Combination Effects
Timolol + Acetazolamide
When these medications are used together, they demonstrate near-complete additivity 9:
- Timolol alone: 36% reduction
- Acetazolamide alone: 48.6% reduction
- When acetazolamide added to timolol: additional 43.2% reduction
- When timolol added to acetazolamide: additional 27.6% reduction
This combination is clinically useful for achieving maximal medical IOP lowering before considering surgical intervention.
Clinical Context and Comparative Efficacy
Prostaglandin analogs (including Vyzulta) are the most effective class for IOP reduction 1. Network meta-analysis confirms that bimatoprost, travoprost, and latanoprost are among the most effective agents, with timolol being slightly less effective 10, 3.
Key efficacy hierarchy from guidelines:
- Prostaglandin analogs/Vyzulta: 28-33% (most effective, once daily)
- Oral acetazolamide: 20-30% (highly effective but systemic side effects limit chronic use)
- Timolol: 26-27% (effective, twice daily)
- Netarsudil: 10-20% (least effective of these four)
Important Clinical Considerations
Baseline IOP matters significantly: Higher baseline IOP predicts better absolute and relative responses to all medications 11. A 20% reduction target is reasonable based on OHTS criteria, but if baseline IOP is markedly elevated, 20% may be insufficient 1, 12, 1.
Vyzulta provides superior 24-hour coverage: Unlike timolol, which has limited nocturnal efficacy, Vyzulta maintains IOP reduction throughout the sleep period 4. This is clinically relevant since nocturnal IOP spikes contribute to glaucoma progression.
Acetazolamide is not for chronic use: While highly effective (20-30% reduction), systemic side effects including paresthesias, metallic taste, electrolyte imbalances, and risk of kidney stones limit its use to short-term IOP crises or perioperative management 1.
Netarsudil has the mildest effect but offers once-daily dosing and a unique mechanism. It's most appropriate as adjunctive therapy rather than monotherapy in patients requiring substantial IOP lowering 1, 8.